TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT05510999

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Lipid soluble pollen extract fraction + water soluble pollen extract fraction
Description: Each capsule contains a combination of 9 mg of lipid soluble pollen extract fraction and 180 mg of water soluble pollen extract fraction. One capsule will be taken twice daily (18 mg/day and 360 mg/day, respectively) for 24 weeks.

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Lipid soluble pollen extract fraction
Description: Each capsule contains 9 mg of lipid soluble pollen extract fraction. One capsule of will be taken twice daily (18 mg/day) for 24 weeks.

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Water soluble pollen extract fraction + cranberry powder
Description: Each capsule contains a combination of 42 mg of water soluble pollen extract and 125 mg of cranberry powder. One capsule will be taken twice daily (84 mg/day and 250 mg/day, respectively) for 24 weeks.
Study: NCT00688389

Intervention type: OTHER
Intervention: case/control
Description: case: infected dengue fever people control:healthy people
Study: NCT03003936

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Dinner timing
Description: Glucose tolerance after a late diner (1 hour before habitual bedtime) differs from early dinner (4 hours before habitual bedtime) due to the concurrence of meal timing with different levels of endogenous melatonin. This effect can be different among risk allele carriers (G) or non-rick allele carriers (C) of the MTNR1B.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Dinner timing
Description: Glucose tolerance after a late diner (1 hour before habitual bedtime) differs from early dinner (4 hours before habitual bedtime) due to the concurrence of meal timing with different levels of endogenous melatonin. This effect can be different among risk allele carriers (G) or non-rick allele carriers (C) of the MTNR1B.
Study: NCT04101903

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: The 6-week Hip Checklist
Description: Comprehensive 9-item structured guide to aid in correct diagnosis of developmental dysplasia of the hip.
Study: NCT01721616

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Azithromycin
Study: NCT02317172

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Gel-based artificial saliva
Description: Gel-based artificial saliva is a novel gel-like, edible moisturizing gel designed to relieve dry mouth.
Study: NCT02060487

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: sildenafil citrate
Description: sildenafil citrate (PDE-5 inhibitor) 5 mg tablet TID until study treatment discontinued or end of study

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: sildenafil citrate
Description: sildenafil citrate (PDE-5 inhibitor) 20 mg tablet TID until study treatment discontinued or end of study

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: sildenafil citrate
Description: sildenafil citrate (PDE-5 inhibitor) 80 mg tablet TID until study treatment discontinued or end of study
Study: NCT03579407

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: BMA cell therapy injection
Description: The bone marrow aspirate will be injected into the affected knee joint.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: BMA cell therapy injection
Description: The bone marrow aspirate will be injected into the affected knee joint.
Study: NCT01874366

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: P11187
Description: * Part I: Step wise dose escalation(10 to 1500 mg, qd, Oral)~* Part II: Step wise dose escalation in multiple dosing (≤ 1500 mg, qd, Oral) for 14 consecutive days.~* Part III: Study drug administered (≤ 1500 mg, qd, Oral) under fasted or fed conditions in two different periods separated by a wash-out interval.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo capsules will be matching in appearance with the active drug capsules of P11187.~* In Part I, there will be up to 6 cohorts of 8 subjects each in single dose assessment. Two subjects from each cohort will be dosed with placebo~* In Part II, there will be 3 cohorts of 12 subjects each and three subjects from each cohort will be dosed with placebo
Study: NCT03269500

Intervention type: OTHER
Intervention: use of nutrition education tools
Description: Use of different nutrition education tools :~* General advice: feeding seniors~* Oral supplementation: instructions for use~* Information about enriched food~* Food modified in texture: chopped masticatory disorders, chopped swallowing disorders, co-mingled~* How should I drink? : With stimulus, texture syrup / nectar, velvety texture, texture compote / cream~* Recipe booklets for people to easily eat (chewing disorders) or recipe with molded texture (swallowing disorders)
Study: NCT03288506

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Google Hangout (VC) group
Description: Feasibility and acceptability of online peer support groups for adults with depression. Groups will be delivered using video-conferencing technology (Google Hangouts).
Study: NCT00783952

Intervention type: DEVICE
Group type: OTHER
Intervention: Cerebral/Somatic Tissue Oximeter device
Description: Measurement of tissue oxygen saturation and simultaneous sampling for blood gas analysis.~Four sensors of the 'Cerebral/Somatic Tissue Oximeter' device will be placed on subject's both sides of the forehead, palm and calf area. Simultaneously, blood samples will be drawn from the pulmonary artery catheter and arterial line for blood gas analyses. The values obtained from the device measurements will be used in a new equation to calculate the mixed venous oxygen saturation. The calculated value will be compared to the real value from the blood gas analysis for accuracy.

Intervention type: DEVICE
Group type: OTHER
Intervention: Pulmonary artery catheter
Description: Blood will be drawn form the pulmonary artery catheter for measurement of mixed venous oxygen saturation.
Study: NCT01883609

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: RTS,S/AS01B
Description: Each RTS,S/AS01B dose will be given intramuscularly, and will contain 50mcg of RTS,S and standard adult dose of AS01

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: RTS,S/AS01B
Description: Each RTS,S/AS01B dose will be given intramuscularly, and will contain 50mcg of RTS,S and standard adult dose of AS01
Study: NCT01721616

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cefazolin
Study: NCT01883609

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: ChAd63 ME-TRAP
Description: ChAd63 ME-TRAP will be given intramuscularly at a dose of 5 x 1010 vp

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: MVA ME-TRAP
Description: MVA ME-TRAP will be given intramuscularly at a dose of 2 x 108 pfu
Study: NCT00953355

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Folate plus metformin
Description: A six-month course of metformin (1700 mg daily) plus folic acid (400 microgram daily).

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo plus metformin
Description: A six-month course of metformin (1700 mg daily) plus placebo
Study: NCT01110096

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Parent Management Training - Oregon (PMTO)
Description: Method to help parents and caregivers manage the behavior of the children they are responsible for.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Motivational interviewing
Description: Communication method to facilitate behavioral change and empower the parents.

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Motivational interviewing
Description: Communication method to facilitate behavioral change and empower the parents.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Dynamic group therapy
Description: Focuses on individual experiences within families and/or parents/children, and that the participants are their own experts.
Study: NCT03369197

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Control: Nasal Cannula
Description: Nasal cannula as per usual care
Study: NCT04242797

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Calmare
Description: Skin is stimulated with an electrical voltage via electrode pads, variably distorted sine wave at \~47 Hz.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: TENS
Description: Skin is stimulated with an electrical voltage via electrode pads, 300 micro-second rectangle pulse at 47 Hz.
Study: NCT01469585

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Doxycycline
Description: 40 mg orally at the start of cycle 3 (study day 57) for 28 days.
Study: NCT00942266

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: fluorouracil
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: fluorouracil
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: leucovorin calcium
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: leucovorin calcium
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: vorinostat
Description: Given orally

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: vorinostat
Description: Given orally

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: pharmacological study
Description: Correlative study

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: pharmacological study
Description: Correlative study
Study: NCT02140879

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Capsule 1 or Capsule 2
Description: Capsules will be consumed on a daily basis during pregnancy. One group, the placebo group of the study, will take capsules (2/day) containing oil '1 ' which is a mixture of corn and soy oils . The other group, the supplement group, will take capsules containing oil '2' which is an algal oil. Both oils are found in our diets.

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Capsule 1 or Capsule 2
Description: Capsules will be consumed on a daily basis during pregnancy. One group, the placebo group of the study, will take capsules (2/day) containing oil '1 ' which is a mixture of corn and soy oils . The other group, the supplement group, will take capsules containing oil '2' which is an algal oil. Both oils are found in our diets.

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Capsule 2
Description: Two capsules will be consumed on a daily basis during pregnancy. The other group, the supplement group, will take capsules containing oil '2' which is an algal oil. Both oils are found in our diets. One group, the placebo group of the study, will take capsules containing oil '1 ' which is a mixture of corn and soy oils .

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Capsule 2
Description: Two capsules will be consumed on a daily basis during pregnancy. The other group, the supplement group, will take capsules containing oil '2' which is an algal oil. Both oils are found in our diets. One group, the placebo group of the study, will take capsules containing oil '1 ' which is a mixture of corn and soy oils .
Study: NCT01199315

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AZD1446
Description: oral capsule, Moderate Release

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: oral capsule
Study: NCT03868878

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Capoeira training
Description: The Capoeira training protocol, based in the modern styles was applied by an instructor with 16 years of experience. The protocol followed the directions of the ABADÁ Capoeira system, being adapted to the sample of older adults of the present study. The experimental protocol for Capoeira progressive training program lasted 12 weeks and was performed twice a week with duration of 60 minutes each. Each session was divided in three parts, being: 1) initial part: consisting of 10 minutes warm-up with recreational activities at low intensity; 2) main part: consisting of 30 minutes of basic movements in the modality and; 3) final part: consisting of 20 minutes with theoretical instructions related to Capoeira and musicality (singing and touch of typical instruments). In order to perform the Capoeira progressive training program, the technical improvement naturally occurred every week, resulting in a higher speed in movements execution and thus to a gradual increase in training intensity.

Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Capoeira training
Description: The Capoeira training protocol, based in the modern styles was applied by an instructor with 16 years of experience. The protocol followed the directions of the ABADÁ Capoeira system, being adapted to the sample of older adults of the present study. The experimental protocol for Capoeira progressive training program lasted 12 weeks and was performed twice a week with duration of 60 minutes each. Each session was divided in three parts, being: 1) initial part: consisting of 10 minutes warm-up with recreational activities at low intensity; 2) main part: consisting of 30 minutes of basic movements in the modality and; 3) final part: consisting of 20 minutes with theoretical instructions related to Capoeira and musicality (singing and touch of typical instruments). In order to perform the Capoeira progressive training program, the technical improvement naturally occurred every week, resulting in a higher speed in movements execution and thus to a gradual increase in training intensity.
Study: NCT04740944

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Salutogenic Approach Based Interview
Description: Salutogenic Approach Based Interview has five basic components. (1) Continuity of health, (2) The story of the person, (3) Health promoting factors, (4) Understanding the health promoting power of tension and strain, (5) Active adaptation In traditional therapy recommended for recovery, more emphasis is placed on negative life events, diagnosis and medication. In the salutogenic approach-based interview, the resources and coping potential of the person are discussed and three healing factors are focused on for the recovery process. These factors are that the participants (1) perceive themselves as more than just a diagnosis and disease, (2) self-discovery and respect for other people's self-discovery, (3) control over their own lives. In the intervention, mental health nurses take part as group leaders. The focus in interviews is therapeutic conversations.
Study: NCT04171011

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Stimulator device
Description: The stimulator device will be used to electrically stimulate the NVB
Study: NCT02399449

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Brand sodium ferric gluconate
Description: brand product

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Brand sodium ferric gluconate
Description: brand product

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Generic sodium ferric gluconate
Description: generic product

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Generic sodium ferric gluconate
Description: generic product
Study: NCT04197037

Intervention type: PROCEDURE
Intervention: Evaluation of sialorrhea through questionnaires that measure daytime and nighttime sialorrhea and the impact on quality of life.
Description: Sialorrhea will be evaluated by the Nocturnal hypersalivation rating scale (NHRS) and Drooling Severity and Frequency Scale (DSFS)
Study: NCT01334840

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Bicarbonated mineral water
Description: Volunteers fasted overnight consumed:~0.5 L of the bicarbonated mineral water without meal or, 0.5 L of the bicarbonated mineral water with meal

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Bicarbonated mineral water
Description: Volunteers fasted overnight consumed:~0.5 L of the bicarbonated mineral water without meal or, 0.5 L of the bicarbonated mineral water with meal

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Mineral water low in mineral content (control)
Description: Volunteers fasted overnight consumed:~0.5 L of the control water without meal or, 0.5 L of the control water with meal

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Mineral water low in mineral content (control)
Description: Volunteers fasted overnight consumed:~0.5 L of the control water without meal or, 0.5 L of the control water with meal
Study: NCT01801007

Intervention type: DEVICE
Group type: OTHER
Intervention: Flow Re-Direction Endoluminal Device (FRED)
Study: NCT03629171

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Liposome-encapsulated Daunorubicin-Cytarabine
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Venetoclax
Description: Given PO
Study: NCT03684993

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Arabic, Gum
Description: natural gum of acacia tree: Antimicrobial, anti-inflammatory medicinal plant used as a traditional oral hygiene substance (anticariogenic). It is used in treating sore throats, colds, bronchitis, toothache, gingival bleeding and mouth ulcers.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Licorice Root
Description: natural licorice, herbal plant to relieve coughs, sore throats, and gastric inflammation. flavouring and sweetening agent. it's anti-caries, soothing anti-inflammatory and anticancer properties benefit against oral diseases and dental caries

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Chlorhexidine
Description: chemical agent used as a mouthwash against cariogenic bacteria. considered the gold standard
Study: NCT00552253

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Levothyroxin treatment
Description: Levothyroxin 100 micogram will be administered once daily 1 hour before meal of just after meal for 3 months, and the dose will be titrate to keep serum TSH level between 0.1\~0.3 mU/L. It will be discontinued for 3 months. Then
Study: NCT00688389

Intervention type: OTHER
Intervention: case/control
Description: case: infected dengue fever people control:healthy people

Intervention type: OTHER
Intervention: case/control
Description: case: infected dengue fever people control:healthy people
Study: NCT00772980

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Neramexane mesylate
Description: Double-blind treatment period of 17 weeks up to 75 mg Neramexane mesylate per day, 12 weeks follow-up.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Double-blind treatment period of 17 weeks placebo, 12 weeks follow-up.
Study: NCT02894606

Intervention type: DRUG
Intervention: Thymoglobulin Induction
Description: The choice of the induction therapy is not a procedure of the study. This choice is made by the practioner, based on the graft recipient profile. This is a predefined group, the Thymoglobulin treatment is not an intervention in the study but must be considered as an exposure that is defined before the patient enters the study.

Intervention type: DRUG
Intervention: Basiliximab Induction
Description: The choice of the induction therapy is not a procedure of the study. This choice is made by the practioner, based on the graft recipient profile. This is a predefined group, the Basiliximab treatment is not an intervention in the study but must be considered as an exposure that is defined before the patient enters the study.
Study: NCT02798172

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Alogliptin and Metformin
Description: The patients in the control group were given metformin (1,000 mg, bid po) and the patients in the intervention group were given metformin (500 mg, bid po) combined with alogliptin (25 mg, qd po)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Alogliptin and Metformin
Description: The patients in the control group were given metformin (1,000 mg, bid po) and the patients in the intervention group were given metformin (500 mg, bid po) combined with alogliptin (25 mg, qd po)
Study: NCT03043300

Intervention type: OTHER
Intervention: Screening Criteria Review
Description: The screening criteria review is an 8 item instrument collecting information during screening about overall health, including self-reported chronic intestinal conditions, immunocompromising conditions, the use of certain medication types (immunosuppressives and antibiotics), and pregnancy status. The instrument will also collect dates of planned travel to South(east) as well as preferred dates for study visits and reminder contacts.~This instrument will be administered verbally by the study team and completed no more than 4 weeks prior to travel departure from the United States.

Intervention type: OTHER
Intervention: Pre-Travel Questionnaire
Description: The pre-travel questionnaire is a 29 item instrument collecting information about baseline characteristics, dietary habits, travel plans, and health history.~This questionnaire will be administered verbally by the study team and completed 1 week prior to travel departure from the United States.

Intervention type: OTHER
Intervention: Pre-Travel Stool Specimen Collection
Description: The pre-travel stool specimen collection will occur 1 week prior to travel departure from the United States.~The processing and analyses of this stool specimen will be performed by the Centers for Disease Control and Prevention.
Study: NCT04786275

Intervention type: DRUG
Intervention: Fentanyl
Description: Standard dose of 2 ug/kg after tetanic stimulation.

Intervention type: OTHER
Intervention: Tetanic stimulation
Description: Standard tetanic stimulation will be used as the stimulus to evaluate response of the intraoperative pain index (NoL) at a standard fentanyl dose.
Study: NCT03874897

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CAR-CLDN18.2 T-Cells
Description: Preconditioning with fludarabine, cyclophosphamide, based chemotherapy regimen at sub-clinical doses~• Chimeric Antigen Receptor T Cells Targeting Claudin18.2

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CAR-CLDN18.2 T-Cells
Description: Preconditioning with fludarabine, cyclophosphamide, based chemotherapy regimen at sub-clinical doses~• Chimeric Antigen Receptor T Cells Targeting Claudin18.2

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CAR-CLDN18.2 T-Cells
Description: Preconditioning with fludarabine, cyclophosphamide, based chemotherapy regimen at sub-clinical doses~• Chimeric Antigen Receptor T Cells Targeting Claudin18.2

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CAR-CLDN18.2 T-Cells
Description: Preconditioning with fludarabine, cyclophosphamide, based chemotherapy regimen at sub-clinical doses~• Chimeric Antigen Receptor T Cells Targeting Claudin18.2

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CAR-CLDN18.2 T-Cells
Description: Preconditioning with fludarabine, cyclophosphamide, based chemotherapy regimen at sub-clinical doses~• Chimeric Antigen Receptor T Cells Targeting Claudin18.2

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PD-1 Monoclonal Antibody
Description: Chimeric Antigen Receptor T Cells Targeting Claudin18.2 with PD-1